Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1*♦
- Tyler E Miller, K. Ghoshal, +5 authors S. Majumder
- Biology, Medicine
- Journal of Biological Chemistry
- 31 October 2008
This is the first study demonstrating a relationship between miR-221/222 expression and HER2/neu overexpression in primary breast tumors that are generally resistant to tamoxifen therapy, and provides the rationale for the application of altered expression of specific miRNAs as a predictive tamoxIFen-resistant breast cancer marker. Expand
Osteopenia and osteoporosis in women with breast cancer.
The management of osteopenia and osteoporosis in women with breast cancer generally does not differ from women without breast cancer, andequate dietary calcium and vitamin D intake, encouraging weight-bearing exercise, and counseling about the relationship between smoking and alcohol and bone loss are all prudent recommendations for overall health and may lessen bone loss and the risk of subsequent osteopsorosis. Expand
Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients
Bvazicumab in combination with weekly docetaxel is active with acceptable toxicities in MBC and E-selectin was statistically significantly associated with response to the combination. Expand
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27(kip1).
A specific miR signature for the tamoxifen- resistant breast cancer and an important cell cycle inhibitor target of the altered miR, which could be used as a prognostic marker for the drug-resistant breast cancer. Expand
Highly sensitive SERS detection of cancer proteins in low sample volume using hollow core photonic crystal fiber.
- Dinish U S, C. Fu, Kiat-Seng Soh, B. Ramaswamy, Anil Kumar, M. Olivo
- Chemistry, Medicine
- Biosensors & bioelectronics
- 15 March 2012
A novel photonic crystal fiber based surface enhanced Raman scattering (SERS) sensing platform for the ultrasensitive detection of cancer proteins in an extremely low sample volume and may lead to the highly sensitive protein sensing methodology for the early detection of diseases. Expand
Giant breast tumors: Surgical management of phyllodes tumors, potential for reconstructive surgery and a review of literature
- M. Liang, B. Ramaswamy, +4 authors W. Carson
- World journal of surgical oncology
- 11 November 2008
Management of the giant phyllodes tumor presents the surgeon with unique challenges and should be limited to patients with pathologic evidence of tumor in the lymph nodes. Expand
Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
It is shown that noncanonical Hedgehog (Hh) signaling is an alternative growth promoting mechanism that is activated in tamoxifen-resistant tumors and Targeting Hh pathway alone or in combination with PI3K/AKT pathway could be a novel therapeutic option in treating endocrine-resistant breast cancer. Expand
Anti-microRNA-222 (Anti-miR-222) and -181B Suppress Growth of Tamoxifen-resistant Xenografts in Mouse by Targeting TIMP3 Protein and Modulating Mitogenic Signal*
- Y. Lu, Satavisha Roy, +5 authors S. Majumder
- Biology, Medicine
- The Journal of Biological Chemistry
- 18 October 2011
It is shown that miR-221 and -222 are up-regulated in tamoxifen-resistant MCF-7 (OHTR) cells and Her2-positive human breast tumors when compared with Her2 negative tumors, and corresponding anti-miRs can be used to render these tumors responsive to tamoxIFen. Expand
Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized…
The addition of lapatinib to trastuzumab in combination with neoadjuvant chemotherapy significantly improves pCR rates in patients with HER2-positive breast cancer. Expand
Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.
- B. Ramaswamy, S. Majumder, +7 authors S. Jacob
- Biology, Medicine
- Molecular endocrinology
- 1 February 2009
The data suggest that estrogen-mediated suppression of PTPRO is probably one of the early events in estrogen-induced tumorigenesis and that expression of PT PRO could facilitate endocrine therapy of breast cancer. Expand